CAPECITABINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H22FN3O6
Molecular Weight	359.3501
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O

InChI

InChIKey=GAGWJHPBXLXJQN-UORFTKCHSA-N

InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/xeloda-drug.htm https://www.drugs.com/mtm/capecitabine.html

Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug which is converted to 5-fluorouracil (5-FU). Both normal and tumor cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2’-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis. Most common adverse reactions (≥30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thymidylate synthase 32 Target ID: CHEMBL1952 Sources: http://www.drugbank.ca/drugs/DB01101 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/16178783 \| https://www.ncbi.nlm.nih.gov/pubmed/1704999 \| https://www.ncbi.nlm.nih.gov/pubmed/25634241 \| https://www.ncbi.nlm.nih.gov/pubmed/8996166	Inhibitor 8297
RNA 19 Target ID: CHEMBL2311222 Sources: http://www.drugbank.ca/drugs/DB01101 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Interacts 323
Cytidine deaminase 5 Target ID: CHEMBL4502 Sources: https://www.ema.europa.eu/en/documents/scientific-discussion/xeloda-epar-scientific-discussion_en.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/18562256	Substrate 661

Conditions

Condition	Modality	Targets	Highest Phase	Product
Colorectal cancer 101 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Primary		Approved 8429	XELODA Approved Use Capecitabine tablets, USP are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer (1.1) oPatients with Dukes’ C colon cancer • Metastatic Colorectal Cancer (1.1) oFirst-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer (1.2) oIn combination with docetaxel after failure of prior anthracycline-containing therapy oAs monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer •Capecitabine tablets, USP are indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine in the adjuvant treatment of Dukes’ C colon cancer. •Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine monotherapy. Use of capecitabine instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer •Capecitabine tablets, USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. •Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. Launch Date 1998
Breast cancer 434 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Primary		Approved 8429	XELODA Approved Use Capecitabine tablets, USP are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer (1.1) oPatients with Dukes’ C colon cancer • Metastatic Colorectal Cancer (1.1) oFirst-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer (1.2) oIn combination with docetaxel after failure of prior anthracycline-containing therapy oAs monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer •Capecitabine tablets, USP are indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine in the adjuvant treatment of Dukes’ C colon cancer. •Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine monotherapy. Use of capecitabine instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer •Capecitabine tablets, USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. •Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. Launch Date 1998

C_max

Value	Dose	Co-administered	Analyte	Population
3515 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29948022	1250 mg/m² 2 times / day multiple, oral dose: 1250 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:		.ALPHA.-FLUORO-.BETA.-ALANINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
9105 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:		CAPECITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
45027 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29948022	1250 mg/m² 2 times / day multiple, oral dose: 1250 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:		.ALPHA.-FLUORO-.BETA.-ALANINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
10238 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:		CAPECITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.78 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:		CAPECITABINE blood	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
65% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf			CAPECITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2500 mg 2 times / day multiple, oral Highest studied dose Dose: 2500 mg, 2 times / day Route: oral Route: multiple Dose: 2500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799	unhealthy, 34-68 n = 7 Health Status: unhealthy Condition: Breast cancer Age Group: 34-68 Sex: F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799	DLT: Hand-and-foot syndrome, Diarrhea... Dose limiting toxicities: Hand-and-foot syndrome (grade 3, 28.6%) Diarrhea (grade 3, 14.29%) Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799
2000 mg 2 times / day multiple, oral MTD Dose: 2000 mg, 2 times / day Route: oral Route: multiple Dose: 2000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799	unhealthy, 41-53 n = 7 Health Status: unhealthy Condition: Breast cancer Age Group: 41-53 Sex: F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799	DLT: Hand-and-foot syndrome... Dose limiting toxicities: Hand-and-foot syndrome (grade 3, 14.29%) Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799
1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	Disc. AE: Coagulopathy, Diarrhea... AEs leading to discontinuation/dose reduction: Coagulopathy Diarrhea Cardiotoxicity Dehydration Renal failure Fetal damage Mucocutaneous disorder (severe) Stevens Johnson syndrome Toxic epidermal necrolysis Hyperbilirubinemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Diarrhea	grade 3, 14.29% DLT	2500 mg 2 times / day multiple, oral Highest studied dose Dose: 2500 mg, 2 times / day Route: oral Route: multiple Dose: 2500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799	unhealthy, 34-68 n = 7 Health Status: unhealthy Condition: Breast cancer Age Group: 34-68 Sex: F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799
Hand-and-foot syndrome	grade 3, 28.6% DLT	2500 mg 2 times / day multiple, oral Highest studied dose Dose: 2500 mg, 2 times / day Route: oral Route: multiple Dose: 2500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799	unhealthy, 34-68 n = 7 Health Status: unhealthy Condition: Breast cancer Age Group: 34-68 Sex: F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799
Hand-and-foot syndrome	grade 3, 14.29% DLT	2000 mg 2 times / day multiple, oral MTD Dose: 2000 mg, 2 times / day Route: oral Route: multiple Dose: 2000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799	unhealthy, 41-53 n = 7 Health Status: unhealthy Condition: Breast cancer Age Group: 41-53 Sex: F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/18398145 Page: p.1799
Cardiotoxicity	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Coagulopathy	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Dehydration	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Diarrhea	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Fetal damage	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Hyperbilirubinemia	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Renal failure	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Stevens Johnson syndrome	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Toxic epidermal necrolysis	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1
Mucocutaneous disorder	severe Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Adjuv ant Colon Cancer\|Metastatic Colorectal Cancer\|Metastatic Breast Cancer Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf Page: p.1

PubMed

Title	Date	PubMed
Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support.	2001	11824880
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.	2001	11772141
Oral fluoropyrimidines: are they the equivalent of parenteral infusional 5-fluorouracil?	2001	11768039
Dose scheduling--Herceptin.	2001	11694785
Disease management considerations: disease management considerations.	2001	11693464
Vision of the future: capecitabine.	2001	11585973
Improving chemoradiotherapy in rectal cancer.	2001	11585972
Integrating oxaliplatin into the management of colorectal cancer.	2001	11585971
Optimizing the use of irinotecan in colorectal cancer.	2001	11585970
Answering patients' needs: oral alternatives to intravenous therapy.	2001	11585969
The evolution of fluoropyrimidine therapy: from intravenous to oral.	2001	11585968
Thymidine phosphorylase (TP) activation: convenience through innovation.	2001	11585967
[Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].	2001	11544827
A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU.	2001 Aug	11587492
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.	2001 Aug	11545541
[Coronary insufficiency after an oral intake of capecitabine].	2001 Aug-Sep	11598548
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.	2001 Dec	11800031
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.	2001 Dec	11720823
Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model.	2001 Jan	11745902
Capecitabine monotherapy in metastatic colorectal cancer.	2001 Jul	11905733
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.	2001 Nov	11768362
Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells.	2001 Nov	11641443
Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.	2001 Nov	11606938
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.	2001 Nov 1	11689577
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.	2001 Nov 1	11689576
Clinical picture: leopard-like vitiligo with capecitabine.	2001 Nov 10	11716883
From the Food and Drug Administration.	2001 Nov 7	11694130
Nonsurgical treatment of hepatocellular carcinoma.	2001 Oct	11685743
Recent advances in the use of radiosensitizing nucleosides.	2001 Oct	11677652
Strategies of medical treatment for metastatic breast cancer (Review).	2001 Oct	11562748
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.	2001 Oct 1	11745247
[New therapeutic options in chemotherapy of advanced colorectal cancer].	2001 Oct 15	11715331
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.	2001 Sep	11697835
Capecitabine: a novel agent for the treatment of solid tumors.	2001 Sep	11604550
[Recent aspects of palliative treatment of metastasized colorectal carcinoma].	2001 Sep 15	11603115
Prediction of the response of colorectal cancer to systemic therapy.	2002 Feb	11902527
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.	2002 Feb	11890118
Future treatment options with capecitabine in solid tumours.	2002 Feb	11841932
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.	2002 Feb	11841931
Clinical experience of capecitabine in metastatic breast cancer.	2002 Feb	11841930
Rational development of capecitabine.	2002 Feb	11841929
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.	2002 Jan	11801546
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.	2002 Jan	11774101
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.	2002 Jan 1	11773165
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.	2002 Jan 15	11786589
[The new chemotherapy of colorectal cancers].	2002 Jan 26	11859739
Drug combination approved for advanced breast cancer.	2002 Jan-Feb	11881602
Xeloda. Warning: drug interaction increase bleeding risks.	2002 Mar	11902039
The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial.	2002 Mar	11836563
Treatment of patients with superficial bladder cancer by intravesical instillation of anticancer drugs plus oral chemotherapy following TUR-Bt: a randomized controlled trial.	2002 Mar-Apr	11836593

Patents

Sample Use Guides

In Vivo Use Guide

Take XELODA with water within 30 min after a meal. Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one week rest period in 3-week cycles.

Route of Administration: Oral

In Vitro Use Guide

After 48 hours treatment of MCF7 cell line with capecitabine, in the concentration of 1147.9 μg/ml 50% of cells have been inhibited. After 72 hours treatment of the cells with capecitabine, at the concentration of 921 μg/ml 50% of cells have been inhibited.

Name

Type

Language

CAPECITABINE

Official Name

English

XELIRI COMPONENT CAPECITIBINE

Common Name

English

CAPECITABINE [VANDF]

Common Name

English

RO-091978000

Code

English

Capecitabine [WHO-DD]

Common Name

English

CAPECITABINE [USP MONOGRAPH]

Common Name

English

CAPECITABINE [JAN]

Common Name

English

Xelox component capecitabine

Common Name

English

CAPECYTABINE

Common Name

English

ECANSYA

Brand Name

English

PENTYL 1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE

Common Name

English

CARBAMIC ACID, (1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-, PENTYL ESTER

Common Name

English

CAPECITABINE SUN

Brand Name

English

CAPECITABINE [USP-RS]

Common Name

English

NSC-759853

Code

English

CAPECITABINE [USP IMPURITY]

Common Name

English

CAPECITABINE [EP MONOGRAPH]

Common Name

English

RO-09-1978000

Code

English

CAPECITABINE [MI]

Common Name

English

CAPECITABINE [MART.]

Common Name

English

CAPECITABINE ACCORD

Brand Name

English

CAPECITABINE [EMA EPAR]

Common Name

English

CAPIIBINE

Common Name

English

capecitabine [INN]

Common Name

English

XELODA

Brand Name

English

RO 09-1978/000

Code

English

CAPECITABINE TEVA

Brand Name

English

CAPECITABINE MEDAC

Brand Name

English

CAPECITABINE [USAN]

Common Name

English

CAPECITABINE [ORANGE BOOK]

Common Name

English

CAPTABIN

Common Name

English

CAPECITABINE [HSDB]

Common Name

English

CAPECITIBINE

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

CAPECITABINE ACCORD (AUTHORIZED: COLONIC NEOPLASMS, BREAST NEOPLASMS, COLORECTAL NEOPLASMS, STOMACH NEOPLASMS)